Original regimen of subcutaneous interleukin 2 (IL2) and interferon alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC) ineligible to receive intravenous (iv) IL2

被引：0
|
作者：
Escudier, B [1 ]
Rossi, JF [1 ]
Ravaud, A [1 ]
Savary, J [1 ]
Pignard, K [1 ]
Negrier, S [1 ]
机构：
[1] CTR LEON BERARD,FRANCH CANC CTR FEDERAT,CTR COORDINATING,IMMUNOTHERAPY GRP,F-69373 LYON,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [1] Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial.
    Negrier, S.
    Perol, D.
    Ravaud, A.
    Bay, J. O.
    Oudard, S.
    Fargeot, P.
    Delva, R.
    Deplanque, G.
    Gravis, G.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 225S - 225S
  • [2] A phase II study of chronic low dose of interleukin-2 (IL2) and α-interferon (IFN-α) in metastatic renal cell carcinoma (MRCC)
    Cengarle, R
    Buzio, C
    Pavone, L
    Santi, R
    Todeschini, R
    Caminiti, C
    Porta, C
    Bidin, L
    Frassoldati, A
    Contu, A
    Passalacqua, R
    ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
  • [3] Results of the first line biochemotherapy with interleukin-2 (IL2), interferon (IFN) and 5-FU and second line biochemotherapy with retinoids and interferon in metastatic renal cell carcinoma (MRCC)
    Zemanova, M
    Petruzelka, L
    ANNALS OF ONCOLOGY, 1998, 9 : 62 - 62
  • [4] Subcutaneous (SC) interleukin-2 (IL2) plus erythropoietin alpha (EPO) in out-patients with metastatic renal cell carcinoma (MRCC) and 3 bad prognosis factors.
    Mayeur, D
    Tourani, JM
    Andre, T
    Bourgeois, H
    Court-Fortune, I
    Moussu, J
    Pfister, C
    Prevot, G
    Sillet-Bach, I
    Tostain, J
    ANNALS OF ONCOLOGY, 2000, 11 : 75 - 75
  • [5] FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
    Erbe, Amy K.
    Wang, Wei
    Goldberg, Jacob
    Gallenberger, Mikayla
    Kim, Kyung Mann
    Carmichael, Lakeesha
    Hess, Dustin
    Mendonca, Eneida A.
    Song, Yiqiang
    Hank, Jacquelyn A.
    Cheng, Su-Chun
    Signoretti, Sabina
    Atkins, Michael
    Carlson, Alexander
    Mier, James W.
    Panka, David J.
    McDermott, David F.
    Sondel, Paul M.
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2159 - 2168
  • [6] High dose Interleukin2 (HD IL2) in metastatic renal cell carcinoma (mRCC) after prior therapy: A single centre experience
    Chow, Shien
    Leach, Rebecca
    Spencer-Shaw, Andrea
    Shaheen, Fadhel
    Thistlethwaite, Fiona C.
    Hawkins, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] INVIVO SYNERGY BETWEEN INTERLEUKIN-2 (IL2) AND INTERFERON-ALPHA (IFN) IN A MURINE MULTIPLE HEPATIC METASTATIC MODEL
    CAMERON, R
    ROSENBERG, SA
    FASEB JOURNAL, 1988, 2 (04): : A689 - A689
  • [8] Subcutaneous (sc) interleukin-2 (IL-2) plus alpha-interferon (IFNα) in out-patients (pts) with metastatic renal cell carcinoma (MRCC).: SCAPP III trial.
    Tourani, JM
    Pfister, C
    Tubiana, N
    Rixe, O
    Benoit, G
    Mayeur, D
    Lucas, V
    Prevot, G
    Untereiner, M
    Favre, R
    ANNALS OF ONCOLOGY, 2000, 11 : 75 - 75
  • [9] IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL2) AND LYMPHOKINE-ACTIVATED NATURAL-KILLER-CELLS - IMPROVEMENT OF CLINICAL-RESPONSES IN METASTATIC RENAL-CELL CARCINOMA PATIENTS PREVIOUSLY TREATED WITH IL2
    ESCUDIER, B
    FARACE, F
    ANGEVIN, E
    CHARPENTIER, F
    NITENBERG, G
    TRIEBEL, F
    HERCEND, T
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) : 1078 - 1083
  • [10] IMPAIRMENT OF INTERLEUKIN II (IL2) PRODUCTION AND THE POTENTIAL FOR IMMUNE RESTORATION WITH IL2 IN CANCER-PATIENTS
    WANEBO, HJ
    PACE, R
    SANDO, J
    JOURNAL OF LEUKOCYTE BIOLOGY, 1985, 38 (01) : 89 - 89
12345